Search results
Results from the WOW.Com Content Network
Active immunotherapy is a type of immunotherapy that aims to stimulate the host's immune system or a specific immune response to a disease or pathogen and is most commonly used in cancer treatments. [ 1 ] [ 2 ] Active immunotherapy is also used for treatment of neurodegenerative disorders , such as Alzheimer's disease , Parkinson's disease ...
Biological response modifiers (BRMs) are substances that modify immune responses. They can be endogenous (produced naturally within the body) or exogenous (as pharmaceutical drugs ), and they can either enhance an immune response or suppress it .
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system.Immunotherapy is designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
Antibody-dependent cellular cytotoxicity. Antibody-dependent cellular cytotoxicity (ADCC), also referred to as antibody-dependent cell-mediated cytotoxicity, is a mechanism of cell-mediated immune defense whereby an effector cell of the immune system kills a target cell, whose membrane-surface antigens have been bound by specific antibodies. [1]
Biologic response modifiers act by altering the immune response of the human body. The mechanism of action is either through interfering with the effect of cytokines, inhibiting the costimulation of T cell activation, or inhibiting B cells. [15] Cytokines are proinflammatory and are responsible for regulating the human immune response. [17]
There are two main categories of immunostimulants: [1] Specific immunostimulants provide antigenic specificity in immune response, such as vaccines or any antigen.; Non-specific immunostimulants act irrespective of antigenic specificity to augment immune response of other antigen or stimulate components of the immune system without antigenic specificity, such as adjuvants and non-specific ...
The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. However, the immune response to certain antigens may be inadequate, especially in the elderly.
To create an immune response, a foreign molecule must be present that antibodies can bind to (i.e. the antigen) and cellular damage must exist. Very often, drugs will not be immunogenic because they are too small to induce immune response. However, a drug can cause an immune response if the drug binds a larger molecule.